Search

Your search keyword '"Dall’O’, Elisa"' showing total 6 results
Start Over Author "Dall’O’, Elisa"
6 results on '"Dall’O’, Elisa"'

1. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations

Author

Bearz, Alessandra, Martini, Jean-François, Jassem, Jacek, Kim, Sang-We, Chang, Gee-Chen, Shaw, Alice T., Shepard, Deborah A., Dall’O’, Elisa, Polli, Anna, Thurm, Holger, Zalcman, Gerard, Garcia Campelo, Maria Rosario, Penkov, Konstantin, Hayashi, Hidetoshi, and Solomon, Benjamin J.

Published
2023
Full Text
View/download PDF

2. Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALKVariant Type and ALKWith or Without TP53Mutations

Author

Bearz, Alessandra, Martini, Jean-François, Jassem, Jacek, Kim, Sang-We, Chang, Gee-Chen, Shaw, Alice T., Shepard, Deborah A., Dall’O’, Elisa, Polli, Anna, Thurm, Holger, Zalcman, Gerard, Garcia Campelo, Maria Rosario, Penkov, Konstantin, Hayashi, Hidetoshi, and Solomon, Benjamin J.

Abstract

Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, improved outcomes compared with crizotinib in patients with previously untreated ALK-positive advanced NSCLC in the phase 3 CROWN study. Here, we investigated response correlates using plasma circulating tumor DNA (ctDNA) and tumor tissue profiling.

Published
2023
Full Text
View/download PDF

3. Abstract CT223: Updated efficacy and safety from the phase 3 CROWN study of first-line lorlatinib vs crizotinib in advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Author

Solomon, Benjamin, primary, Bauer, Todd, additional, Mok, Tony, additional, Liu, Geoffrey, additional, Mazieres, Julien, additional, de Marinis, Filippo, additional, Goto, Yasushi, additional, Kim, Dong-Wan, additional, Wu, Yi-Long, additional, Dvorkin, Mikhail, additional, Jassem, Jacek, additional, López-López, Froylán, additional, Soo, Ross, additional, Polli, Anna, additional, Dall'O, Elisa, additional, Iadeluca, Laura, additional, Toffalorio, Francesca, additional, and Felip, Enriqueta, additional

Published
2022
Full Text
View/download PDF

4. Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with ALK+ advanced non–small cell lung cancer (NSCLC).

Author

Solomon, Benjamin J., primary, Bauer, Todd Michael, additional, Felip, Enriqueta, additional, Liu, Geoffrey, additional, Mazieres, Julien, additional, de Marinis, Filippo, additional, Goto, Yasushi, additional, Kim, Dong-Wan, additional, Laktionov, Konstantin K., additional, Blackhall, Fiona Helen, additional, Dall’O, Elisa, additional, Polli, Anna, additional, Toffalorio, Francesca, additional, and Mok, Tony S. K., additional

Published
2022
Full Text
View/download PDF

5. Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.

Author

Bearz, Alessandra, primary, Martini, Jean-Francois, additional, Jassem, Jacek, additional, Kim, Sang-We, additional, Chang, Gee-Chen, additional, Shaw, Alice Tsang, additional, Shepard, Deborah, additional, Dall’O, Elisa, additional, Polli, Anna, additional, Thurm, Holger C., additional, Zalcman, Gerard, additional, Campelo, Rosario Garcia, additional, Penkov, Konstantin, additional, Hayashi, Hidetoshi, additional, and Solomon, Benjamin J., additional

Published
2022
Full Text
View/download PDF

6. Abstract LB043: Efficacy of Lorlatinib in Treatment-Naïve Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations

Author

Bearz, Alessandra, primary, Martini, Jean-François, additional, Jassem, Jacek, additional, Kim, Sang-We, additional, Chang, Gee-Chen, additional, Shaw, Alice, additional, Shepard, Deborah, additional, Dall'O', Elisa, additional, Polli, Anna, additional, Thurm, Holger, additional, Zalcman, Gerard, additional, Campelo, Maria Rosario Garcia, additional, Penkov, Konstantin, additional, Hayashi, Hidetoshi, additional, and Solomon, Benjamin J., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results